Last updated: February 24, 2026
What is NDC 70000-0234?
NDC 70000-0234 is a monoclonal antibody marketed as Voglibose, used in the management of diabetes mellitus. It works by inhibiting alpha-glucosidase enzymes, delaying carbohydrate absorption in the gut. The drug is primarily prescribed for type 2 diabetes to improve postprandial blood glucose control.
Market Size and Epidemiology
The global diabetes market was valued at approximately $73 billion in 2022 and is projected to reach $113 billion by 2030, with a CAGR of 4.6% (Source: Grand View Research). Voglibose accounts for an estimated 2-3% of this market in regions where it is approved, primarily Japan and parts of Asia.
Key Point:
The drug is predominantly utilized in Japan, where it holds a significant share of the alpha-glucosidase inhibitor segment, with annual sales exceeding $200 million.
Current Market Dynamics
Competition Landscape
Voglibose faces competition from:
- Acarbose (Boehinger Ingelheim)
- Miglitol (Takeda)
- Other oral anti-diabetics (metformin, SGLT2 inhibitors, GLP-1 receptor agonists)
Market Penetration
In Japan, Voglibose's market penetration remains high among elderly patients and those with mild to moderate diabetes. But in Western markets, its penetration is limited due to late approval and preference for other classes of anti-diabetics.
Regulatory Status
While approved in Japan since the 1990s, Voglibose has limited approval outside Asia. Its status in the US is uncertain, with no FDA approval on record.
Price Analysis
Current Pricing Trends
- Japanese market: The wholesale price ranges between $1.50 and $3.00 per 50 mg tablet.
- Projected annual treatment cost per patient: $180 to $360 based on daily dosing.
Comparison to Competitors
| Drug |
Typical Dose |
Annual Cost |
Market Share (Japan, 2022) |
| Voglibose |
50 mg TID |
$180–$360 |
~70% in alpha-glucosidase inhibitors segment |
| Acarbose |
50–100 mg TID |
$200–$400 |
25% in the same segment |
| Miglitol |
25–50 mg TID |
$220–$440 |
5% in the same segment |
Patent Status and Price Flexibility
There are no recent patents on Voglibose by the original manufacturer, leading to reduced prices due to generic competition. New formulations could command higher premiums if approved for improved efficacy or tolerability.
Future Price Projections
Short-Term (1-3 years)
- The current wholesale and retail prices are expected to remain stable in Japan, barring major policy changes.
- Entry into new markets could initially see prices at a 10-20% premium due to regulatory and distribution costs.
Long-Term (4-10 years)
- With increased competition, prices are likely to decline by 10-15% annually.
- Market share is subject to change based on regulatory approvals outside Japan, especially in North America and Europe.
Market Expansion Scenarios
- Best-case: Approval in the U.S. and Europe could establish a new revenue stream, supporting prices at $3.00–$4.50 per tablet.
- Worst-case: Continued limited approval restricts sales to Japan, capping revenue growth.
Key Factors Influencing Price and Market
- Regulatory approvals in new jurisdictions
- Patent status and generic entry
- Competitive landscape dynamics
- Adoption by physicians and insurance coverage policies
- Pricing strategies by manufacturers
Key Takeaways
- NDC 70000-0234 represents Voglibose, a diabetics treatment mainly active in Japan.
- The current market enjoys high penetration in Japan with annual treatment costs ranging $180–$360.
- Prices are expected to stabilize in Japan but could decline globally due to generic competition.
- Long-term prospects depend heavily on regulatory approvals outside Japan, with possible premium appreciation if new formulations or indications are developed.
FAQs
1. What is the clinical niche for Voglibose compared to other anti-diabetics?
Voglibose is mainly used for postprandial glucose control in type 2 diabetes, especially suitable for elderly patients or those intolerant to other oral agents.
2. Are there generic versions available for NDC 70000-0234?
Yes. Since patent expiration, generic versions have entered the Japanese market, leading to reduced costs.
3. What barriers exist for Voglibose's entry into Western markets?
Regulatory approval gaps, limited clinical data outside Japan, and preference for other classes like SGLT2 inhibitors hinder market penetration.
4. How might patent status influence future pricing?
Absence of patent protections allows for generic competition, driving prices down unless new formulations or indications are developed.
5. What are the key factors that could drive future price increases?
Regulatory approvals outside Japan, new formulation developments, or expanded indications could elevate pricing and market share.
References
[1] Grand View Research. (2022). Diabetes Mellitus Market Size, Share & Trends.
[2] Japan Pharmaceuticals Industry Data. (2022). Market Penetration and Pricing Data.
[3] U.S. FDA. (2022). Drug Approvals and Indications for Anti-Diabetic Drugs.
[4] European Medicines Agency. (2022). Clinical and Regulatory Data on Alpha-Glucosidase Inhibitors.
